Tracking Real World Psychedelic Use Nationwide
Kate Reynolds from Rocky Mountain Poison and Drug Safety (RPMDS) discusses how NSIHT tracks real world psychedelic use nationwide.
delphiwp
Psychedelics and Reimbursement in Europe
Join Lia Mix, CEO of Delphi, and Floris Wolswijk, Senior Policy and Research Partner at Delphi, for the third Delphi Insight Session on reimbursement pathways for psychedelic therapies in Europe.
Economic, Clinical, and Real-world Insights
The latest research on psychedelic-assisted therapies in August provides critical insights into economic feasibility, implementation models, and clinical effectiveness across diverse patient groups.
Cross-Diagnostic Potential of Psychedelics
New psychedelic studies highlight cross-indication applicability of MDMA-assisted therapy, risks with naturalistic use, and potential life-extending effects of psilocybin.
How New Psychedelic Studies Inform Clinical Implementation
New psychedelic studies highlight durable effects of psilocybin therapy, Delphi consensus, and pivotal Phase II and III trials.
Conversation with Tyler Norris
The second Delphi Insight Session features a conversation with Tyler Norris on the integration of psychedelics into the broader healthcare system, the challenges, and roadmap towards making this integration happen.
Economic Impacts, Therapeutic Advances, and Emotional Benefits
New psychedelic studies highlight ketamine’s economic benefits, psilocybin’s spiritual impact, and DMT’s potential therapeutic uses.
Scaling Psychedelics
In this session, you’ll learn about the essential organizations and activities we must focus on now to ensure psychedelics can be brought to scale as soon as possible after FDA approval.
Delphi’s Strategic Outlook
The first Delphi Insight Session – an introduction to Delphi, our work, and our vision for an integrated future.
Rapid and Sustained Psychedelic Treatments Show Promise in Recent Clinical Trials
Recent psychedelic research provides crucial insights for drug developers, advocates, and policy leaders, demonstrating the practical potential of psychedelic treatments to transform mental health care delivery.
